Literature DB >> 10947925

MR imaging of intradural tumors of the cervical spine.

R R Lee1.   

Abstract

MR imaging is the modality of choice for intradural spinal tumors because of its unsurpassed depiction of soft tissues, the use of intravenous contrast, the absence of beam-hardening artifacts, and the ability to image in multiple planes. Intradural tumors are classified as intradural-extramedullary and intradural-intramedullary. MR imaging techniques that best depict these tumors are reviewed, and several examples of tumors are described and illustrated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947925

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  5 in total

Review 1.  Intradural spinal tumors: current classification and MRI features.

Authors:  Kasim Abul-Kasim; Majda M Thurnher; Paul McKeever; Pia C Sundgren
Journal:  Neuroradiology       Date:  2007-12-15       Impact factor: 2.804

Review 2.  Hemangioblastomas of the lower spinal region: report of four cases with preoperative embolization and review of the literature.

Authors:  Alessandra Biondi; Giuseppe K Ricciardi; Tierry Faillot; Laurent Capelle; Rémy Van Effenterre; Jacques Chiras
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Magnetic resonance imaging of the cervical spine: comparison of 2D T2-weighted turbo spin echo, 2D T2*weighted gradient-recalled echo and 3D T2-weighted variable flip-angle turbo spin echo sequences.

Authors:  T Meindl; S Wirth; S Weckbach; O Dietrich; M Reiser; S O Schoenberg
Journal:  Eur Radiol       Date:  2008-09-24       Impact factor: 5.315

4.  Delay in diagnosis of primary intradural spinal cord tumors.

Authors:  David Segal; Zvi Lidar; Akiva Corn; Shlomi Constantini
Journal:  Surg Neurol Int       Date:  2012-05-14

5.  Experience of operative treatment in 27 patients with intraspinal neurilemmoma.

Authors:  Haibo Li; Yiping Weng; Dong Zhou; Luming Nong; Nanwei Xu
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.